Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 70Terminated 23Recruiting 18Active not recruiting 17Unknown 15Withdrawn 6Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 4Breast Neoplasms 3Stomach Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Tongue Squamous Cell Carcinoma 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Resectable Esophageal Squamous Cell Carcinoma 1Rare Tumour 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Hypoxia 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1CLDN18.2 Positive 1Biliary Tract Neoplasms 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Gemcitabine 20130-nm albumin-bound paclitaxel 8irinotecan sucrosofate 7Oxaliplatin 6Leucovorin 6Fluorouracil 6Taxes 5Drug Therapy 5Albumin-Bound Paclitaxel 4toripalimab 3S 1 (combination) 3Paclitaxel 3Injections 3surufatinib 2camrelizumab 2Specimen Handling 2Pemetrexed 2Pancreaticoduodenectomy 2Irinotecan 2Exercise 2Capecitabine 2Blood Specimen Collection 2zimberelimab 1sintilimab 1potassium oxonate 1pembrolizumab 1nimotuzumab 1netrin-1 inhibitor NP137 1gimeracil 1folfirinox 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Pancreatic Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT07578337 2026-05-13

NUMANTIA-2

Nelum Corp

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT07383922 2026-02-04

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Phase 3 Not yet recruiting
524 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06177522 2025-11-18

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Jinling Hospital, China

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
50 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡